Switzerland
· Delayed Price · Currency is CHF Roche Holding AG Company Description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally.
The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases.
In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
| Country | Switzerland |
| Founded | 1896 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 103,249 |
| CEO | Thomas Schinecker |
Contact Details
Address: Grenzacherstrasse 124 Basel Switzerland | |
| Phone | 41 61 688 88 80 |
Stock Details
| Ticker Symbol | RO |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0012032113 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas Schinecker | Group Chief Executive Officer |
| Dr. Severin Schwan Ph.D. | Executive Chairman |
| Dr. Alan Hippe | Chief Financial Officer |
| Dr. Bruno Eschli | Head of Investor Relations |
| Claudia Bockstiegel | General Counsel |
| Pascale Schmidt | Chief Compliance Officer |
| Barbara Schadler | Head of Group Communications |
| Cristina A. Wilbur | Chief People Officer |
| Dr. Nicolas Dunant | Head of Group Media Relations |
| Boris L. Zaitra | Head of Corporate Business Development |